Compassionate Cultivation makes first sale under expanded medical cannabis program

The floodgates are now officially open for Texas' expanded medicinal cannabis program. Cannabis company Compassionate Cultivation announced Aug. 29 its first sale to a terminal cancer patient: Charlotte Friedley of the Austin metro, who is being treated for non-Hodgkin's lymphoma. It is the first time any of the medicinal cannabis companies approved by the state has served a cancer patient, according to the announcement. During its recently completed session, the Texas Legislature passed House…
Source: Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

ConclusionsThe MTX population pharmacokinetic model developed in this study might provide useful information for establishing personalized therapy involving MTX for the treatment of adult patients with NHL.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Unfortunately, the word ”Group” is missed in the article title of the original publication. It has been corrected by this erratum.
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
ConclusionsPola PK was well characterized with no clinically meaningful DDIs with R/G-CHP. Findings are consistent with previous studies of pola  + R/G, and support pola + R/G-CHP use in previously untreated diffuse large B-cell lymphoma.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Authors: Kienle DL, Stilgenbauer S Abstract Introduction: PI3K inhibition with idelalisib (at that time CAL-101) was at the forefront of the development of molecularly targeted therapies in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) and follicular lymphoma. However, after initial approval, subsequent trials identified specific immune-mediated and infectious toxicity that led to a reduced use and stopped the further development of this agent. PI3K inhibition as a treatment paradigm fell out of favor compared to other developments such as BTK or BCL2 inhibitors.Areas covered: This review prov...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
(National Foundation for Cancer Research) National Foundation for Cancer Research-backed drug and drug delivery technology receives assent from US Food and Drug Administration for T-cell non-Hodgkin's lymphoma clinical trials. The milestone represents another example of promising translational cancer research supported by the organization and its donors.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
The cancer experience may be marked by repeat stressors and/or traumas. The aim of our study was to assess traumatic events in a group of patients diagnosed with lymphoma and to determine which of these contribute to the development of Post-Traumatic Stress Disorder/PTSD. Two weeks after receiving a diagnosis of lymphoma, patients were referred for an assessment of peritraumatic distress (using the Peritraumatic Distress Inventory/PDI) and peritraumatic dissociation (using the Peritraumatic Dissociative Experiences Questionnaire/PDEQ). Three months after the diagnosis, we recorded the following parameters: the patients' wo...
Source: Frontiers in Psychiatry - Category: Psychiatry Source Type: research
Abstract OBJECTIVES: In the Asian population, patterns and risk factors for de novo malignancies after solid-organ transplant are not well understood. MATERIALS AND METHODS: Insurance claims from Taiwan's National Health Institute Research Database from 1997 to 2011 revealed 687 deceased-donor heart transplant recipients, 5038 kidney transplant recipients (50% living related-donor, 50% deceased-donor transplants), and 2127 liver transplant recipients (mainly living related-donor transplants, 30% deceased-donor transplants). During the follow-up period, rates of malignancy incidence were calculated with standa...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - Category: Transplant Surgery Authors: Tags: Exp Clin Transplant Source Type: research
ConclusionsGenetic risk variants inIL1B andIL6 may affect the association between IM and TCL, possibly by influencing T-cell activation, growth, and differentiation in the presence of IM, thereby decreasing risk of immune cell proliferation.
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
CONCLUSION: The incidence rates of lymphoma in the Golestan province are relatively high and vary geographically, with a higher incidence observed in the western area. Such differences may reflect unknown lifestyle and environmental determinants linked to ethnic susceptibility differing between the two areas. PMID: 32126782 [PubMed - in process]
Source: Archives of Iranian Medicine - Category: Middle East Health Authors: Tags: Arch Iran Med Source Type: research
Asha Karadwal, Shailja Chatterjee, Kush Pathak, Robin SabharwalJournal of Oral and Maxillofacial Pathology 2020 24(4):77-81 Lymphomas are the third-most common cancer of the oral cavity after squamous cell carcinomas and salivary gland tumors. It is characterized by proliferation of lymphoid cells and their precursor. Diffuse B-cell non-Hodgkin lymphoma is the most common histological type of lymphoma in the head-and-neck region and most commonly affects older men in their seventh decade of life.
Source: Journal of Oral and Maxillofacial Pathology - Category: ENT & OMF Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Health Management | Lymphoma | Non-Hodgkin's Lymphoma | Pharmaceuticals